Occudo Quantitative Strategies LP Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Occudo Quantitative Strategies LP grew its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 96.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 22,512 shares of the biopharmaceutical company's stock after buying an additional 11,052 shares during the quarter. Occudo Quantitative Strategies LP's holdings in Royalty Pharma were worth $574,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Royalty Pharma by 25.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 66,501 shares of the biopharmaceutical company's stock worth $1,696,000 after buying an additional 13,376 shares in the last quarter. Ethic Inc. lifted its holdings in shares of Royalty Pharma by 132.6% in the 4th quarter. Ethic Inc. now owns 20,342 shares of the biopharmaceutical company's stock worth $519,000 after acquiring an additional 11,597 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in shares of Royalty Pharma by 24.6% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,161,304 shares of the biopharmaceutical company's stock worth $29,625,000 after acquiring an additional 228,964 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Royalty Pharma by 36.2% in the 4th quarter. Deutsche Bank AG now owns 3,189,964 shares of the biopharmaceutical company's stock valued at $81,376,000 after purchasing an additional 847,704 shares in the last quarter. Finally, Corton Capital Inc. bought a new position in shares of Royalty Pharma during the 4th quarter valued at $278,000. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Trading Down 4.1%

NASDAQ:RPRX traded down $1.40 during midday trading on Tuesday, reaching $32.85. 2,525,610 shares of the stock traded hands, compared to its average volume of 3,433,995. The stock has a market capitalization of $18.94 billion, a P/E ratio of 22.62, a PEG ratio of 2.31 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The company has a fifty day moving average of $32.42 and a 200 day moving average of $30.06. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.50.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. The firm had revenue of $839.00 million for the quarter, compared to analysts' expectations of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date is Friday, May 16th. Royalty Pharma's payout ratio is 47.57%.

Analysts Set New Price Targets

Several research firms have weighed in on RPRX. StockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Monday, May 12th. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Finally, Morgan Stanley assumed coverage on Royalty Pharma in a report on Friday. They set an "overweight" rating and a $51.00 target price for the company. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Royalty Pharma currently has a consensus rating of "Buy" and an average target price of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.